Alliance Pharma PLC Appointment of Non-Executive Directors (5965K)

TIDMAPH

RNS Number : 5965K

Alliance Pharma PLC

17 December 2018

 
 For immediate release                      17 December 2018 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Appointment of Non-Executive Directors

Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical company, announces the appointment of two independent Non-Executive Directors, Jo Le Couilliard and Richard Jones, who bring further international business experience and capital markets expertise to the Board. Jo and Richard, who both have substantial pharmaceutical and healthcare experience gained at listed companies, will join the Board on 1 January 2019.

As an executive, Jo Le Couilliard served a total of almost 20 years at GlaxoSmithKline ("GSK"), leaving in June 2018 to focus on non-executive roles. Her recent positions at GSK have included Senior Vice President and Area Head, Asia Pacific, a role in which she was responsible for GSK's sales and marketing in Australia, New Zealand, Korea, Taiwan and Southeast Asia. Jo, who qualified as an accountant at PwC, is currently a non-executive director of the UK-listed healthcare companies Cello Health plc and Circassia Pharmaceuticals plc.

Richard Jones has extensive capital markets, growth company and board experience. Richard is currently the Chief Financial Officer of Mereo BioPharma Group plc, an AIM-listed clinical stage biopharmaceutical company focused on rare diseases before which he was Chief Financial Officer of AIM-listed Shield Therapeutics plc. Prior to these positions, Richard, who qualified as an accountant at PwC, worked in investment banking for a total of 12 years focusing predominantly on the healthcare sector.

David Cook, Alliance Pharma's Chairman, commented: "I am delighted to welcome Jo and Richard to Alliance's Board. They bring a huge breadth of relevant and varied experience to Alliance. Jo's extensive experience at GSK included a senior sales and marketing position in Asia Pacific, which represents Alliance's fastest growing region. Richard, from his work as an investment banker and as a financial executive, brings a depth of relevant capital markets experience. I look forward to their contribution to the Company's ongoing development into a leading international healthcare business."

The following information is disclosed pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies.

Joanna Susan Le Couilliard, 55 years of age, has been a director or partner of the following companies during the five years preceding the date of this announcement.

   Current directorships                                                   Past directorships 
   Cello Health plc                                                           GlaxoSmithKline Pte Ltd 

Circassia Pharmaceuticals plc Glaxo Wellcome Manufacturing Pte Ltd

General Healthcare Group Ltd

Duke NUS Medical School

Richard Crispin Morgan Jones, 52 years of age, has been a director or partner of the following companies during the five years preceding the date of this announcement.

 
 Current directorships             Past directorships 
 Mereo BioPharma Group plc         Shield Therapeutics PLC 
                                  -------------------------------- 
 Mereo BioPharma 1 Limited         Shield TX (UK) LTD 
                                  -------------------------------- 
 Mereo BioPharma 2 Limited         Shield TX (Switzerland) AG 
                                  -------------------------------- 
 Mereo BioPharma 3 Limited         Shield TX GmbH 
                                  -------------------------------- 
 Mereo BioPharma 4 Limited         Shield Holdings AG 
                                  -------------------------------- 
 Mereo BioPharma Ireland Limited   Iron Therapeutics Holdings AG 
                                  -------------------------------- 
 Mereo US Holdings Inc             Iron Therapeutics Switzerland 
                                    AG 
                                  -------------------------------- 
 Mereo MereoCo Inc                 Phosphate Therapeutics Ltd 
                                  -------------------------------- 
                                   Krysto Pharma Ltd 
                                  -------------------------------- 
                                   Wolverleigh Consultants Limited 
                                  -------------------------------- 
 

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies in respect of the appointments of Jo Le Couilliard and Richard Jones.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan + 44 (0) 20 7466 5000

Mark Court / Sophie Wills

Numis Securities Limited + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black

Investec Bank plc [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / David Herring

Notes to editors:

Alliance Pharma plc is an international specialty pharmaceutical company.

Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAGMMMZRDVGRZM

(END) Dow Jones Newswires

December 17, 2018 02:01 ET (07:01 GMT)